George Washington University Study Asks: Can Nilotinib be Repurposed from use for Specific Cancer to use for Parkinson’s Disease?

George Washington University Study Asks: Can Nilotinib be Repurposed from use for Specific Cancer to use for Parkinson’s Disease?

There is tremendous value in identifying new purposes for existing drugs. Recently, Georgetown University Medical Center (GUMC) embarked on a project to do just that for Parkinson’s disease with a cancer drug called nilotinib (Tasigna). They found that the drug in...
GW University Selected as First Site for High-Risk Cutaneous Squamous Cell Carcinoma Clinical Trial

GW University Selected as First Site for High-Risk Cutaneous Squamous Cell Carcinoma Clinical Trial

Industry sponsors Regeneron and Sanofi have selected George Washington University (GW) Cancer Center as the first global site for a clinical trial for patients with high-risk cutaneous squamous cell carcinoma. The study will compare disease-free survival of patients...

Pin It on Pinterest